Literature DB >> 10193522

The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours.

M G Luciani1, A Stoppacciaro, G Peri, A Mantovani, L P Ruco.   

Abstract

AIMS: Monocyte chemotactic protein 1 (MCP-1) and interleukin 8 (IL-8) are small, inducible proteins with chemotactic activity for specific subsets of leucocytes. The possibility that MCP-1 and IL-8 are produced in tissues involved by Hodgkin's disease, thus contributing to the inflammatory-type background of the lesion, was investigated.
METHODS: The presence of RNA transcripts for MCP-1 and IL-8 was investigated in biopsy samples of 24 cases of Hodgkin's disease, 17 non-Hodgkin's malignant lymphomas, 30 solid tumours, and 30 histologically normal tissues by means of reverse transcription-polymerase chain reaction (RT-PCR)/Southern blot analysis.
RESULTS: MCP-1 expression was detected in 23 of 24 cases of Hodgkin's disease, in seven of 17 cases of B cell non-Hodgkin's lymphoma, and in seven of 14 cases of reactive lymphoid hyperplasia. IL-8 was present in six of 14 cases of Hodgkin's disease, and was seen only rarely in B cell non-Hodgkin's lymphoma and in reactive lymphoid tissues. MCP-1 and IL-8 RNA transcripts were detected in 13 of 25 carcinomas originating from the lung, breast, thyroid, and ovary.
CONCLUSIONS: These findings are consistent with the possibility that MCP-1 and IL-8 are two additional cytokines involved in the pathogenesis of Hodgkin's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10193522      PMCID: PMC395651          DOI: 10.1136/mp.51.5.273

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  35 in total

Review 1.  Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines.

Authors:  A Mantovani
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

Review 2.  High endothelial venules (HEVs): specialized endothelium for lymphocyte migration.

Authors:  J P Girard; T A Springer
Journal:  Immunol Today       Date:  1995-09

Review 3.  Human chemokines: an update.

Authors:  M Baggiolini; B Dewald; B Moser
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Expression of interleukin-8 correlates with vascularity in human gastric carcinomas.

Authors:  Y Kitadai; K Haruma; K Sumii; S Yamamoto; T Ue; H Yokozaki; W Yasui; Y Ohmoto; G Kajiyama; I J Fidler; E Tahara
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

5.  Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome.

Authors:  A Bellocq; M Antoine; A Flahault; C Philippe; B Crestani; J F Bernaudin; C Mayaud; B Milleron; L Baud; J Cadranel
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

6.  Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density.

Authors:  H D Foss; H Herbst; S Gottstein; G Demel; I Araujó; H Stein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Monocyte chemoattractant protein-1 in idiopathic pulmonary fibrosis and other interstitial lung diseases.

Authors:  K Iyonaga; M Takeya; N Saita; O Sakamoto; T Yoshimura; M Ando; K Takahashi
Journal:  Hum Pathol       Date:  1994-05       Impact factor: 3.466

8.  Regulation of the macrophage content of neoplasms by chemoattractants.

Authors:  B Bottazzi; N Polentarutti; R Acero; A Balsari; D Boraschi; P Ghezzi; M Salmona; A Mantovani
Journal:  Science       Date:  1983-04-08       Impact factor: 47.728

9.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

10.  Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.

Authors:  K Matsushima; K Morishita; T Yoshimura; S Lavu; Y Kobayashi; W Lew; E Appella; H F Kung; E J Leonard; J J Oppenheim
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  7 in total

1.  Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma.

Authors:  Toni Valković; Antica Duletić-Načinović; Sanja Stifter; Milena Hasan; Ita Hadžisejdić; David Zombori; Blaženka Grahovac; Nives Jonjić
Journal:  Clin Exp Med       Date:  2010-03-16       Impact factor: 3.984

2.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

3.  Primary central nervous system lymphoma secretes monocyte chemoattractant protein 1.

Authors:  Ryuhei Kitai; Kazuyo Ishisaka; Kazufumi Sato; Takahiro Sakuma; Takahiro Yamauchi; Yoshiaki Imamura; Hideki Matsumoto; Toshihiko Kubota
Journal:  Med Mol Morphol       Date:  2007-03-29       Impact factor: 2.309

Review 4.  The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma.

Authors:  Kyle P D'mello; Lei Zhao; Erin C Kaser; Ziwen Zhu; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Med Oncol       Date:  2021-04-09       Impact factor: 3.064

Review 5.  Hodgkin disease and the role of the immune system.

Authors:  Alana A Kennedy-Nasser; Patrick Hanley; Catherine M Bollard
Journal:  Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.969

Review 6.  Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

Authors:  Manja Idorn; Per Thor Straten
Journal:  Cells       Date:  2018-08-17       Impact factor: 6.600

7.  Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue.

Authors:  Alex Reza Gholiha; Peter Hollander; Liza Löf; Anders Larsson; Jamileh Hashemi; Johan Mattsson Ulfstedt; Daniel Molin; Rose-Marie Amini; Eva Freyhult; Masood Kamali-Moghaddam; Gunilla Enblad
Journal:  Cancers (Basel)       Date:  2021-12-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.